tiprankstipranks
BioCryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
US Market
BCRX
BioCryst
RESEARCH TOOLSreports
Want to see BCRX full AI Analyst Report?

BioCryst (BCRX) Stock Forecast & Price Target

2,730 Followers
See the Price Targets and Ratings of:

BCRX Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
BioCryst
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BCRX Stock 12 Month Forecast

Average Price Target

$22.43
▲(136.09% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for BioCryst in the last 3 months. The average price target is $22.43 with a high forecast of $32.00 and a low forecast of $13.00. The average price target represents a 136.09% change from the last price of $9.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","12":"$12","19":"$19","26":"$26","33":"$33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.42857142857143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$13.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12,19,26,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.19,10.944615384615384,12.69923076923077,14.453846153846154,16.20846153846154,17.963076923076922,19.71769230769231,21.472307692307695,23.22692307692308,24.981538461538463,26.736153846153847,28.49076923076923,30.245384615384616,{"y":32,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.19,10.208351648351648,11.226703296703297,12.245054945054946,13.263406593406593,14.281758241758244,15.30010989010989,16.31846153846154,17.33681318681319,18.355164835164835,19.373516483516486,20.391868131868137,21.410219780219784,{"y":22.42857142857143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.19,9.483076923076922,9.776153846153846,10.069230769230769,10.362307692307692,10.655384615384616,10.948461538461538,11.241538461538461,11.534615384615385,11.827692307692308,12.12076923076923,12.413846153846155,12.706923076923077,{"y":13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.29,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.63,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.19,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$32.00Average Price Target$22.43Lowest Price Target$13.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BCRX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$32
Buy
236.84%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)
Citizens JMP Analyst forecast on BCRX
Jonathan Wolleben
Citizens JMP
Citizens JMP
$25→$28
Buy
194.74%
Upside
Reiterated
05/07/26
BioCryst price target raised to $28 from $25 at CitizensBioCryst price target raised to $28 from $25 at Citizens
Wedbush Analyst forecast on BCRX
Laura Chico
Wedbush
Wedbush
$22→$21
Buy
121.05%
Upside
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Penumbra (NYSE: PEN) and BioCryst (NASDAQ: BCRX)
Needham Analyst forecast on BCRX
Serge Belanger
Needham
Needham
$18→$16
Buy
68.42%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: BioCryst (NASDAQ: BCRX) and Regeneron (NASDAQ: REGN)
RBC Capital Analyst forecast on BCRX
Brian Abrahams
RBC Capital
RBC Capital
$14→$13
Buy
36.84%
Upside
Reiterated
05/06/26
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)
TD Cowen Analyst forecast on BCRX
Stacy Ku
TD Cowen
TD Cowen
$30
Buy
215.79%
Upside
Reiterated
05/06/26
BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target
Bank of America Securities Analyst forecast on BCRX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW) and BioCryst (NASDAQ: BCRX)
Evercore ISI Analyst forecast on BCRX
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$17
Buy
78.95%
Upside
Initiated
02/18/26
Evercore ISI Resumes Coverage with a Buy Rating on BioCryst (BCRX)
Cantor Fitzgerald Analyst forecast on BCRX
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$26
Buy
173.68%
Upside
Reiterated
01/12/26
Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)
Barclays Analyst forecast on BCRX
Gena Wang
Barclays
Barclays
$11→$9
Hold
-5.26%
Downside
Reiterated
11/03/25
Barclays Sticks to Their Hold Rating for BioCryst (BCRX)
Jefferies Analyst forecast on BCRX
Maury Raycroft
Jefferies
Jefferies
$15
Buy
57.89%
Upside
Reiterated
10/14/25
BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on BCRX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$32
Buy
236.84%
Upside
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)
Citizens JMP Analyst forecast on BCRX
Jonathan Wolleben
Citizens JMP
Citizens JMP
$25→$28
Buy
194.74%
Upside
Reiterated
05/07/26
BioCryst price target raised to $28 from $25 at CitizensBioCryst price target raised to $28 from $25 at Citizens
Wedbush Analyst forecast on BCRX
Laura Chico
Wedbush
Wedbush
$22→$21
Buy
121.05%
Upside
Reiterated
05/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Penumbra (NYSE: PEN) and BioCryst (NASDAQ: BCRX)
Needham Analyst forecast on BCRX
Serge Belanger
Needham
Needham
$18→$16
Buy
68.42%
Upside
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: BioCryst (NASDAQ: BCRX) and Regeneron (NASDAQ: REGN)
RBC Capital Analyst forecast on BCRX
Brian Abrahams
RBC Capital
RBC Capital
$14→$13
Buy
36.84%
Upside
Reiterated
05/06/26
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX)
TD Cowen Analyst forecast on BCRX
Stacy Ku
TD Cowen
TD Cowen
$30
Buy
215.79%
Upside
Reiterated
05/06/26
BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target
Bank of America Securities Analyst forecast on BCRX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
04/16/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW) and BioCryst (NASDAQ: BCRX)
Evercore ISI Analyst forecast on BCRX
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$17
Buy
78.95%
Upside
Initiated
02/18/26
Evercore ISI Resumes Coverage with a Buy Rating on BioCryst (BCRX)
Cantor Fitzgerald Analyst forecast on BCRX
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$26
Buy
173.68%
Upside
Reiterated
01/12/26
Cantor Fitzgerald Sticks to Its Buy Rating for BioCryst (BCRX)
Barclays Analyst forecast on BCRX
Gena Wang
Barclays
Barclays
$11→$9
Hold
-5.26%
Downside
Reiterated
11/03/25
Barclays Sticks to Their Hold Rating for BioCryst (BCRX)
Jefferies Analyst forecast on BCRX
Maury Raycroft
Jefferies
Jefferies
$15
Buy
57.89%
Upside
Reiterated
10/14/25
BioCryst's Strategic Acquisition of ATXS: A Catalyst for Long-Term Growth and Profitability
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioCryst

3 Months
Tazeen AhmadBank of America Securities
Success Rate
9/19 ratings generated profit
47%
Average Return
-0.24%
Copying Tazeen Ahmad's trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of -0.24% per trade.
1 Year
Serge BelangerNeedham
Success Rate
12/22 ratings generated profit
55%
Average Return
+8.20%
Copying Serge Belanger's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +8.20% per trade.
2 Years
Tazeen AhmadBank of America Securities
Success Rate
14/19 ratings generated profit
74%
Average Return
+11.86%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 73.68% of your transactions generating a profit, with an average return of +11.86% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BCRX Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
23
21
15
8
7
Buy
0
0
1
3
4
Hold
2
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
22
16
11
11
In the current month, BCRX has received 11 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BCRX average Analyst price target in the past 3 months is 22.43.
Each month's total comprises the sum of three months' worth of ratings.

BCRX Financial Forecast

BCRX Earnings Forecast

Next quarter’s earnings estimate for BCRX is $0.16 with a range of -$0.04 to $0.38. The previous quarter’s EPS was -$2.98. BCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.
Next quarter’s earnings estimate for BCRX is $0.16 with a range of -$0.04 to $0.38. The previous quarter’s EPS was -$2.98. BCRX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.

BCRX Sales Forecast

Next quarter’s sales forecast for BCRX is $185.69M with a range of $160.10M to $234.88M. The previous quarter’s sales results were $156.41M. BCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.
Next quarter’s sales forecast for BCRX is $185.69M with a range of $160.10M to $234.88M. The previous quarter’s sales results were $156.41M. BCRX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year BCRX has Performed in-line its overall industry.

BCRX Stock Forecast FAQ

What is BCRX’s average 12-month price target, according to analysts?
Based on analyst ratings, BioCryst Pharmaceuticals’s 12-month average price target is 22.43.
    What is BCRX’s upside potential, based on the analysts’ average price target?
    BioCryst Pharmaceuticals has 136.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BCRX a Buy, Sell or Hold?
          BioCryst Pharmaceuticals has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is BioCryst Pharmaceuticals’s price target?
            The average price target for BioCryst Pharmaceuticals is 22.43. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $32.00 ,the lowest forecast is $13.00. The average price target represents 136.09% Increase from the current price of $9.5.
              What do analysts say about BioCryst Pharmaceuticals?
              BioCryst Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of BCRX?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.